Neuroscience Drug Discovery
Charles River is committed to developing a comprehensive portfolio of technologies and capabilities to support drug discovery and safety studies for therapies targeting neurological and psychiatric diseases. These experimental methodologies can be used for early discovery to identify drug targets and optimize lead compounds as well as for later pharmacology and toxicology studies. Each method is validated in relevant cell-based assay systems and in vivo animal models of disease to generate predictive data that maximizes efficient translation from preclinical to clinical studies. Additionally, new technologies are added to the portfolio to improve sensitivity, efficacy, and reproducibility at every stage of the drug discovery continuum.
Our neuroscience toolkit encompasses biomarker development, pathology, behavioral and cognitive testing, physiology, and state-of-the-art imaging methods. Robust preclinical testing in rodent and nonrodent models, combined with comprehensive pathology services and market-leading cardiac risk assessment services, helps shorten the time required to move a promising lead compound into the clinic.
Some of the CNS-specific translational tools that are available include:
- Measurement of electrical activity using electrophysiology in single neurons and brain slices
- Measurement of changes in sleep state and seizures using EEG
- Gait and posture changes measured by fine motor kinematic analysis
- Cognitive testing using touchscreen testing, novel object recognition, and other methods
- Imaging methods including PET, CT, MRI, and SPECT
- Microdialysis combined with bioanalysis of samples